MPN expert Dr. Rami Komrokji of Moffitt Cancer Center discusses various genetic marker subsets of myeloproliferative neoplasms (MPNs) and how these alterations affect what type of treatment a patient should receive. Dr. Komrokji points out that genetic testing allows doctors to make a firm diagnosis and choose different courses of treatment.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo